ERD-308 |
| Catalog No.GC36001 |
ERD-308은 ER 양성 유방암 치료를 위한 매우 강력한 von Hippel-Lindau 기반 PROTAC 분해효소 에스트로겐 수용체(ER) 분해제입니다. ERD-308은 두 세포주(MCF-7 및 T47D ER+ 세포에서 0.17 nM 및 0.43 nM의 DC50(단백질 분해의 50%를 일으키는 농도))에서 5 nM만큼 낮은 농도에서 95% 이상의 ER 분해를 유도합니다. , 각각).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2320561-35-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
ERD-308 is a highly potent PROTAC degrader of estrogen receptor (ER) for ER positive breast cancer treatment. ERD-308 induces >95% of ER degradation at concentrations as low as 5 nM in both cell lines (DC50 (concentration causing 50% of protein degradation) of 0.17 nM and 0.43 nM in MCF-7 and T47D ER+ cells, respectively)[1]. DC50: 0.17 nM (ER in MCF-7 cells), 0.43 nM (ER in T47D ER+ cells)[1].
[1]. Hu J, et al. Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER). J Med Chem. 2019 Feb 14;62(3):1420-1442.
Average Rating: 5 (Based on Reviews and 39 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *